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ABSTRACT: Regular consumption of low-dose aspirin reduces the occurrence of colorectal, esophageal, stomach, and
gastrointestinal cancers. The underlying mechanism is unknown but may be linked to inhibition of angiogenesis.
Because the effectivedoses of aspirin are consistentwith the inhibitionof cyclooxygenase-1 inplatelets,weused liquid
chromatography with tandem mass spectrometry analyses and immunoassays of human platelet releasates coupled
with angiogenesis assays to search for the mediators of these effects. Blood or platelet-rich plasma from healthy
volunteers stimulated with platelet activators produced a broad range of eicosanoids. Notably, preincubation of
platelets with aspirin, but not with a P2Y12 receptor antagonist, caused a marked reduction in the production of 11-
hydroxyeicosatetraenoic acid (HETE) and 15(S)-HETE, in addition to prostanoids such as thromboxane A2. Releasates
from activated platelets caused cell migration and tube formation in cultured human endothelial cells and stimulated
the sprouting of rat aortic rings in culture. These proangiogenic effects were absent when platelets were treated
with aspirin but returned by coincubation with exogenous 15(S)-HETE. These results reveal 15(S)-HETE as
a major platelet cyclooxygenase-1 product with strong proangiogenic effects. Thus, 15(S)-HETE represents a
potential target for the development of novel antiangiogenic therapeutics, and blockade of its production may
provide a mechanism for the anticancer effects of aspirin.—Rauzi, F., Kirkby, N. S., Edin, M. L., Whiteford,
J. Zeldin, D. C., Mitchell, J. A., Warner, T. D. Aspirin inhibits the production of proangiogenic 15(S)-HETE by
platelet cyclooxygenase-1. FASEB J. 30, 4256–4266 (2016). www.fasebj.org
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Epidemiologic data have established that regular con-
sumptionof aspirin reduces theoccurrenceof somecancers,
notably colorectal, esophageal, stomach, and gastrointesti-
nal (1–4). The mechanism underlying this remarkably sig-
nificant effect is unknown, although itmaybe inpart linked
to reductions in angiogenesis.
Aspirinactsby irreversibly inhibiting thecyclooxygenase
(COX) enzyme, and this explains its anti-inflammatory,
analgesic, antipyretic, and antiplatelet effects (5–7). These
effects of aspirin are produced at notably different dosages;
the anti-inflammatory effects are seen only at very high
dosage (many grams), the analgesic effects require high to
mediumdosage (around 600mg), the antipyretic effects are
exerted at medium dosage (300–600 mg), and the anti-
platelet effects are fully achieved with a low dosage
(75–100mg) (7). Notably, the anticancer effects of aspirin
are displayed at low dosages (4), consistent with those
that inhibit platelets (8) and markedly below dosages
required for analgesic or antiinflammatory effects.
Platelets are blood components central to hemostasis.
Upon activation, platelets release large amounts of arachi-
donic acid (AA) from themembrane phospholipids largely
through the activity of group IVA cytosolic phospholipase
A2 (9, 10). The AA released is rapidly metabolized by
multiple enzymaticpathways (9, 10).Thebest characterized
of these pathways within platelets is the conversion of AA
to thromboxane (TX)A2, which is dependent upon the ac-
tions of COX-1 and TX synthase. TXA2 is a potent pro-
thrombotic hormone that drives platelet aggregation and
thus the formation of blood thrombi. Regular consumption
of low-dose aspirin irreversibly inhibits COX-1. This in turn
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blocks the formation of TXA2, which leads to reduced
platelet activation and diminished thrombus formation. In
contrast to the lack of insight regarding the ability of low-
dose aspirin to reduce cancer, blockadeof theproductionof
TXA2 provides a clear mechanism to explain low-dose
aspirin’s antithrombotic effectiveness (5–8).
Building upon the evidence that platelet COX-1 is the
therapeutic target of low-dose aspirin,we characterized the
eicosanoids produced by activated platelets and their sen-
sitivities to clinically relevant antiplatelet levels of aspirin.
The eicosanoids identified as major AA-derived platelet
products were then investigated for their influence on cell
targets within the vasculature (i.e., platelets, leukocytes,
and endothelial cells that could be relevant to the influences
of aspirin upon cancer progression). From these studies we
propose that15(S)-hydroxyeicosatetraenoicacid (HETE) is a
previously unidentified major COX-1 product of plate-
lets whose inhibition could provide a mechanistic ex-
planation for some of the anticancer effects of aspirin.
MATERIALS AND METHODS
Blood collection and ethics
Blood from healthy volunteers was collected by venepuncture
into lepirudin (250 mg/ml). All experiments were subject to
written informed consent and appropriate local ethical approval
(healthy volunteer samples: St. Thomas’s Hospital Research
Ethics Committee, reference 07/Q0702/24; patient samples:
South East National Health Service Research Ethics Committee)
and in accordance with Declaration of Helsinki principles. As
reportedpreviously, platelet countsweremade to confirm that all
samples were within the normal range (9, 11–13).
Preparation of whole-blood and platelet-rich
plasma samples for liquid chromatography with
tandem mass spectrometry analysis
Blood was incubated with vehicle, aspirin (100 mM), the P2Y12
receptor antagonist prasugrel active metabolite (PAM) (3 mM; a
gift from AstraZeneca), or aspirin + PAM. Part of the blood was
centrifuged (175 g; 15 min) to obtain platelet-rich plasma (PRP).
Platelets in bothwhole blood andPRPwere then activated under
static conditions (in initial experiments) or under stirring condi-
tions in a light transmission aggregometer by the addition of
collagen (30 mg/ml) (Takeda Pharmaceuticals, Deerfield, IL,
USA), TRAP-6 (30 mM) (Sigma-Aldrich, St. Louis, MO, USA), or
A23187 (50 mM) and incubation for 5 min. Plasma was then
quickly separated from the samples by centrifugation (2000 g,
5 min, 4°C) and stored at 280°C for eicosanomic analysis, as
previously described (14, 15). In brief, HyperSep Retain PEP SPE
cartridges (Thermo Fisher Scientific, Waltham, MA, USA) were
preconditionedwith a solution of 0.1% acetic acid/5%methanol
and spiked with 30 ng each of internal standards. Plasma
(0.25ml)wasdiluted in 0.1%acetic acid/5%methanol containing
0.009 mM butylated hydroxytoluene and added to the column.
Samples were then washed with two volumes of 0.1% acetic
acid/5% methanol, eluted in 1 ml of ethyl acetate and 1 ml
methanol, dried by vacuum centrifugation at 37°C, and recon-
stituted in 30% ethanol. AA-derived metabolites were then sep-
arated by reverse-phaseHPLC on a 13 150mm, 5mmLunaC18
(2) column (Phenomenex, Torrance, CA, USA) and quantified
usingaMDSSciexAPI3000 triplequadrupolemassspectrometer
(AppliedBiosystems, FosterCity, CA,USA)with negative-mode
electrospray ionization and multiple reaction monitoring. Data
were captured and analyzed using Analyst 1.5.1 software. Rel-
ative response ratios of each analyte were used to calculate
concentrations, and extraction efficiency for each sample was
calculated based on recovery of the internal standards.
Enzymatic immune assay for 15(S)-HETE
Enzymatic immune assay (EIA) assay was performed in accor-
dancewith the kit insert (CaymanChemical Co., AnnArbor,MI,
USA). In brief, PRP and whole blood samples were diluted 1:10
and assayed in parallel to known 15(S)-HETE standards, a
maximum binding control, nonspecific binding control, and
blank on a 96-well plate coated with goat anti-IgG antibodies.
Light transmission aggregometry
As we have reported previously (16), PRP prepared from blood
treated with lepirudin was pretreated with aspirin (100 mM)
(Sigma-Aldrich), PAM (3 mM), or aspirin + PAM and then in-
cubated under stirring (1200 rpm; 1min) before being stimulated
with collagen (3 mg/ml) with or without the addition of U46619
(2mM), prostaglandin (PG)D2/PGE2 (1mM), 11(R)-HETE, 15(S)-
HETE, and/or 15(R)-HETE (all 1 mM) (Cayman Chemical Co.).
Aggregation was followed over 7 min, and the area under the
curve (AUC) of platelet aggregation responses was determined.
96-well plate aggregometry
To measure responses to a broad panel of platelet agonists
across a range of concentrations, we performed additional
studies using 96-well plate-based aggregometry, as we have
described previously (11, 13). In brief, 100-ml aliquots of PRP
preincubated with aspirin (100 mM), PAM (3 mM), aspirin +
PAM, or vehicle were loaded into 96-well microtiter plates con-
taining A23187 (Ca2+ ionophore, 1.25–40 mM) (Sigma-Aldrich),
ADP (0.1–30 mM; Sigma-Aldrich), collagen (0.1–30 mg/ml), epi-
nephrine (1 nM–100 mM) (Labmedics/Chronolog, Oxfordshire,
United Kingdom), TRAP-6 amide (0.25–5 mM), or the TXA2-
mimetic U46619 (0.1–4 mM) (Enzo Lifesciences, Exeter, United
Kingdom) with or without 5-HETE, 11-HETE, 12-HETE, or
15-HETE (1 mM). Plates were shaken vigorously for 16 min at
37°C in a microtiter plate reader (Sunrise; Tecan, Ma¨nnedorf,
Switzerland), during which time absorbance (595 nm) was
recorded every 15 s. Aggregation (in percent) was calculated
using the initial absorbance of each well (0%), and the absor-
bance of platelet-poor plasma as 100% reference.
Neutrophil chemotaxis
Polymorphonuclear leukocytes were isolated from blood of
healthy volunteers by centrifugation (400 g, 30 min) using a
double-density gradientmedium (Hystopaque 1109–Hystopaque
1007) and suspended at 4 3 106 cells/ml in RPMI 1640 medium
with 0.1% bovine serum albumin. The effects on neutrophil che-
motaxis of leukotriene (LT)B4 at 1–100 nM, 5-HETE, 11-HETE,
12(S)-HETE, and 15-HETE at 0.3 and 3 mM and vehicle were
studied using 96-well chemotaxis plates with a 3 mM pore size
upper filter (3.2-mm diameter sites, 30-ml 96-well plate, 3 mm)
(ChemoTx; Neuro Probe, Gaithersburg, MD, USA) incubated for
1.5 h (37°C, 5%CO2). Each experimental conditionwas assessed in
quadruplicate,withcellmigrationdeterminedbythecolorimetric/
fluorescent indicator AlamarBlue (Thermo Fisher Scientific).
Tube formation assay
Immortalized human microvascular endothelial cells (line
HMEC-1; Centers for Disease Control and Prevention, Atlanta,
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GA, USA) were cultured in RPMI 1640 medium with 10% fetal
bovine serum (FBS) onto 48-well plates coated with 100 ml/well
basement membrane extract in the presence of vehicle or 15(S)-
HETE. Tube formation was visualized by time-lapse micros-
copy (magnitude, 34) over 16 h using an inverted microscope
(IX81; Olympus, Tokyo, Japan) with a digital camera (Orca-ER;
Hamamatsu, Hamamatsu City, Japan). Image acquisition was
performed using Cell M software (Olympus). After the 16 h in-
cubation, images were taken in phase (original magnification,
310) and in fluorescence (original magnification,310) by label-
ing cells with calcein AM. The number of branching points was
counted after 4, 8, and 16 h incubation using Image J software
(National Institutes of Health, Bethesda, MD, USA). In experi-
ments investigating the effects of platelet incubates on HMEC-1
cells, platelets in PRP were activated under stirring conditions
in a light transmission aggregometer by the addition of collagen
(30 mg/ml) (Takeda) or TRAP-6 (30 mM) (Sigma-Aldrich) and
incubation for 5 min [as for preparation for liquid chromatogra-
phy with tandem mass spectrometry (LC-MS/MS) analysis]
before being added directly to the cells together with an equal
volume of RPMI 1640 medium + 2% FBS. For experiments in-
vestigating the effects of platelet releasates, plasma was quickly
separated from the samples by centrifugation (2000 g, 5min, 4°C)
before combination with RPMI 1640 medium + 2% FBS and ad-
dition to the HMEC-1 cells.
Cell migration assay
Confluent HMEC-1 cells on 6-well plates were scraped in a
straight line using a p200 tip to create a “scratch” and incubated
(37°C; 5% CO2) in RPMI 1640 medium with 10% FBS in the
presence of vehicle or 15(S)-HETE. HMEC-1migration was then
visualized by time-lapsemicroscopy (magnitude,310) over 20 h
using anOlympus IX81 invertedmicroscopewith aHamamatsu
Orca-ER digital camera, and image acquisition was performed
using Cell M software (Olympus). The percentage of area cov-
ered by cells throughout the 20 h incubation was calculated.
Platelet releasates were prepared as previously described.
Rat aortic ring assay
Thoracic aortas from 180–200 g Wistar rats (Charles River Lab-
oratories,Wilmington,MA, USA)were sliced into equal sections
and incubated (37°C; 5% CO2) overnight in serum-free Opti-
MEM (Invitrogen, Carlsbad, CA, USA) before being embedded
in type I collagen (1 mg/ml) in E4 medium (Invitrogen). Rings
were then incubated (37°C; 5% CO2) in Opti-MEM (Thermo
FisherScientific)plus1%FBS (PAALaboratories/GEHealthcare,
Little Chalfont, United Kingdom) in the presence of platelet
releasates and/or VEGF (10 nM), 15(S)-HETE (1mM), or vehicle.
Emergent angiogenic sprouts from rat aortas were counted after
4 d in culture. All animal experiments were conducted in accor-
dance with the British Home Office regulation (Scientific Proce-
dures) Act. Images were captured using an Olympus IX81
inverted microscope with a Hamamatsu Orca-ER digital camera,
and image acquisition was performed using Cell M software
(Olympus). Platelet releasates were prepared as described above.
RESULTS
Eicosanoid formation in whole blood and PRP
To test the source of eicosanoids produced inwhole blood,
incubations were made of blood or PRP from healthy
volunteers together with A23187 (50 mM), collagen
(30 mg/ml), TRAP-6 (30 mM), or PBS. Although a broad
range of eicosanoids was detected (Table 1), those pro-
duced in the highest amounts to collagen and TRAP-6
were 12-HETE, TXA2, 15-HETE, and 11-HETE, with sim-
ilar levels in PRP and whole blood (Fig. 1). 5-HETE was a
very prominent product of whole blood stimulated with
A23187 but was absent in PRP.
Eicosanoid formation in whole blood and PRP
in the presence of antiplatelet treatment
Focusing on the major eicosanoid products identified
above, aspirin alone or in combination with prasugrel
blocked the production of TXA2, PGE2, and PGD2, along
with 11-HETE and 15-HETE, in whole blood and in PRP.
EIA indicated that the 15(S)-HETEenantiomerwasamajor
product and that aspirin inhibited its formation (Table 2).
The addition of 15(R)-HETE standards to the EIA verified
that the assay was highly selective for 15(S)-HETE, pro-
viding further confirmation that 15(S)-HETEwasproduced
by the activated platelets. The productions of 12-HETE in
blood and PRPwere not significantly affected by aspirin or
PAM but were reduced by the combination of aspirin and
PAM (Fig. 2). Levels of 5-HETE did not increase after
stimulation of blood or PRP with collagen or TRAP-6 and
were not affected by any of the treatments tested.
Effect of platelet COX-1-derived prostanoids
and 11(R)-, 15(S,R)-HETE on
platelet aggregation
Having established 11-HETE and 15(S)-HETE as platelet
COX-1 products, the effects of these on platelet aggregation
were tested alongside the other COX-1 products at the
proportions identified by LC-MS/MS analysis (i.e., these
experiments were aimed to clarify the net effect of the
combination of COX-1-dependent products upon platelet
aggregation). Aggregation induced by collagen (3 mg/ml)
in thepresence of vehicle (light transmission aggregometry;
AUC,5036118)wasgreatly reducedbyaspirin (AUC,926
18) and largely restored by the addition of U46619 (2 mM)
as a surrogate for TXA2 (AUC, 352 6 86). This effect was
blunted by further addition of PGE2 (1 mM) and PGD2
(1mM)(TXA2/PGE2/PGD2, 2:1:1;AUC, 1766 42) butwas
unaffected by further addition of the HETE enantiomers
(1 mM) [TXA2/PGE2/PGD2/11(R)-HETE/15(R)-HETE/
15(S)-HETE, 2:1:1:1:1:1; AUC, 141 6 25] (n = 4 for all).
Neither exogenous 11-HETE, 12(S)-HETE, 15(S)-HETE,
5-HETE (all 1mM),nor 12-LOX inhibitionwithbaicalein or
nordihydroguaiaretic acid (both 10 mM) affected platelet
aggregation to collagen or TRAP-6 (data not shown).
Effect of HETE isoforms on
neutrophil chemotaxis
The effects on neutrophil chemotaxis of 11(R)-HETE,
15(S)-HETE, 5-HETE, andof the 12(S)-HETE stereoisomer
(0.3–3 mM) were compared with those of LTB4, a potent
neutrophil chemoattractant. LTB4 (1–100 nM) produced a
strong chemoattractant effect on neutrophils, inducing
migration of 80–90% of cells (Fig. 3). 5-HETE (3 mM) and
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12(S)-HETE (3 mM) also exhibited strong chemotactic ef-
fects on 50–70%of neutrophils, but 11(R)-HETEand15(S)-
HETE were without effect.
Effect of incubates of platelets activated by
collagen or TRAP-6 in the presence or absence
of aspirin on HMEC-1 tube formation
Incubates of platelets stimulated with TRAP-6 (30 mM) or
collagen (30 mg/ml) robustly promoted tube formation of
HMEC-1 cells (Fig. 4), but this effect was absent when
platelets were pretreated with aspirin (Fig. 4).
Effect of 15(S)-HETE on HMEC-1 tube
formation in the presence of releasates from
aspirin- or vehicle-treated platelets
stimulated with TRAP-6 or collagen
Releasates from platelets stimulated with TRAP-6
(30 mM) or collagen (30 mg/ml) robustly promoted
tube formation of HMEC-1 cells (Fig. 5). This effect
was strongly impaired in releasates from aspirin-treated
platelets but was fully restored by the addition of 15(S)-
HETE (1 mM). 15(S)-HETE (1 mM) did not increase the
proangiogenic effects of releasates from non-aspirin-
treated platelets.
Effect of 15(S)-HETE on HMEC-1 migration in
the presence of releasates from aspirin- or
vehicle-treated platelets stimulated with
TRAP-6 or collagen
Releasates from platelets stimulated with TRAP-6 pro-
duced a small but significant increase in cell migration
in the scratch assay (field cover: control, 55 6 4%;
+TRAP-6, 67 6 4%; P , 0.05). This effect was absent in
response to releasates from aspirin-treated platelets
stimulated with TRAP-6 (486 3%) but was restored by
the addition of 15(S)-HETE (1 mM) (58 6 4%; P , 0.05)
(n = 4 for all).
Effect of 15(S)-HETE on formation of sprouts
from rat aortic rings in the presence of
releasates from aspirin- or vehicle-treated
platelets stimulated with TRAP-6 or collagen
Incubation of rat aortic ringswith releasates fromplatelets
stimulatedwith collagenorTRAP-6 led to robust increases
TABLE 1. LC-MS/MS analysis of production of eicosanoids in whole blood (pg/ml)
Eicosanoid Vehicle + Collagen (30 mg/ml) +TRAP-6 (30 mM) +A23187 (50 mM)
12-HETE 8463 6 4440 235,817 6 55,654 43,267 6 16,587 838,833 6 77,940
TXB2 102 6 32 17,618 6 2704 24,072 6 6528 38,433 6 3835
15-HETE 749 6 120 10,460 6 1913 14,227 6 4207 34,450 6 2158
11-HETE 111 6 18 4084 6 711 6177 6 2075 11,305 6 1107
17,18-DHET 2633 6 311 2825 6 549 2844 6 350 2995 6 614
12,13-EpOME 2851 6 494 2565 6 356 2764 6 466 2778 6 475
13-HODE 1755 6 237 1972 6 251 1957 6 261 3401 6 496
PGF2a 1200 6 92 1640 6 143 1939 6 294 1882 6 42
5-HETE 697 6 136 1270 6 237 1212 6 200 217,467 6 34,158
PGE2 31 6 8 1053 6 182 2006 6 875 4770 6 1068
9-HODE 768 6 106 1016 6 100 1056 6 148 1518 6 93
19,20-DiHDPA 874 6 147 941 6 189 955 6 182 907 6 168
PGD2 17 6 4 779 6 195 1083 6 438 2652 6 543
5,6-EET 401 6 68 647 6 113 718 6 77 2368 6 120
14,15-DHET 461 6 17 503 6 42 497 6 28 516 6 41
19,20-EpDPE 420 6 69 454 6 51 465 6 76 620 6 126
9,12,13-THOME 1247 6 768 340 6 122 1210 6 833 1180 6 801
20-HETE 327 6 89 336 6 75 265 6 97 389 6 72
19-HETE 290 6 14 315 6 28 274 6 18 312 6 38
11,12-DHET 285 6 15 302 6 26 304 6 22 313 6 27
9,10-EpOME 311 6 70 282 6 26 311 6 52 390 6 45
8,9-DHET 147 6 19 148 6 23 152 6 17 171 6 27
14,15-EET 60 6 4 113 6 11 102 6 7 402 6 30
9,10,13-THOME 56 6 15 108 6 25 66 6 23 162 6 29
6ketoPGF1a 22 6 5 96 6 16 119 6 34 248 6 45
8,9-EET 72 6 11 88 6 5 97 6 7 224 6 11
5,6-DHET 51 6 3 70 6 19 62 6 8 213 6 68
8isoPGF2a 25 6 1 63 6 16 92 6 25 110 6 6
11,12-EET 19 6 6 40 6 2 48 6 4 184 6 9
17,18-EpETE 2 6 1 1 6 1 2 6 1 12 6 1
Whole blood was incubated under static conditions for 30 min at 37°C in the presence of vehicle
control, collagen (30 mg/ml), TRAP-6 (30 mM), or Ca2+ ionophore (A23187; 50 mM) and then
centrifuged (1300 g; 24°C) to produce plasma samples. Data are shown as means 6 SEM. Data are
ordered by amounts of eicosanoids (pg/ml) produced in response to collagen (n = 4 for each).
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in the number of sprouts comparable to those caused by
VEGF, a well-characterized proangiogenic factor (Fig. 6).
However, the number of sprouts was strongly reduced
in aortic rings incubated with releasates from platelets
that had been treated with aspirin. The loss of sprout-
stimulating activitywas restored by the addition of 15(S)-
HETE (1 mM) to the aspirin-treated releasates.
DISCUSSION
Although the use of low-dose aspirin for the secondary
prevention of vascular thrombotic events has been estab-
lished for many years (8), it is only recently that epidemi-
ologic and observational analyses have revealed that
long-term use of aspirin at low doses confers protection
against particular types of cancers, notably colorectal,
esophageal, stomach, and gastrointestinal (1–4). As out-
lined above, aspirin at low dose exerts its strongest effect
on platelets, with higher doses being required for systemic
analgesic and anti-inflammatory effects. Although the
mechanism of action of aspirin in reducing cancer pro-
gression is not clear, the rational conclusion to be drawn
fromavailable epidemiologic andpharmacokinetic data is
that much of this beneficial effect is due to inhibition of
platelet COX-1. Therefore,we hypothesized that exposure
of platelets to aspirin limited the production of pro-
cancerous and/or proangiogenic factors associated with
COX-1. To test this concept, we conducted an unbiased
LC-MS/MS analysis of the products of blood and platelet-
rich plasma exposed to known platelet activators in
control conditions in the presence of aspirin and in the
presence of the platelet inhibitor PAM, which does not
inhibit COX-1. We conducted incubations under stirring
conditionsbecause this better predicts platelet reactivity in
thebody thanstatic conditions (17).Asothers andwehave
reported previously (9, 18, 19), activated platelets produce
a broad range of AA-derived eicosanoids. Notably, in our
studies we found 11-HETE and 15-HETE to be major
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Figure 1. LC-MS/MS analysis of production of TXB2, PGE2, PGD2, 5-HETE, 11-HETE, 12-HETE, and 15-HETE in whole blood and
PRP. Whole blood and PRP from healthy volunteers was incubated for 30 min at 37°C in the presence of Ca2+ ionophore (A23187;
50 mM), collagen (30 mg/ml), TRAP-6 (30 mM), or vehicle and then centrifuged (1300 g; 24°C) to produce plasma samples.
Signiﬁcant and similar increases in the levels of TXB2 (A), PGE2 (B), PGD2 (C), 5-HETE (D), 11-HETE (E), 12-HETE (F), and
15-HETE (G) were found in PRP and whole blood stimulated with A23187, collagen, or TRAP-6 compared with vehicle. The level of
5-HETE increased in whole blood only in response to A23187 but did not increase in PRP (P , 0.01; n = 5; 2-way ANOVA).
TABLE 2. Production of 15(S)-HETE (ng/ml) by platelets in response
to collagen or TRAP-6 in the presence of vehicle, aspirin, PAM, or
aspirin + PAM
Treatment
Collagen (30 mg/ml) TRAP-6 (30 mM)
PRP
Whole
blood PRP
Whole
blood
Control 22.6 6 0.8 14.3 6 2.2 10.4 6 1.2 8.8 6 0.7
+ Aspirin 7.7 6 1.1* 6.2 6 1.0* 3.8 6 0.7* 3.5 6 0.3*
+ PAM 16.2 6 0.8* 14.4 6 1.2 9.2 6 1.7 7.8 6 0.8
+ Aspirin +
PAM
5.6 6 0.7* 5.0 6 0.6* 2.9 6 0.5* 3.1 6 0.2*
Data obtained by ANOVA with Dunnett posttest (n = 4 for all).
Data are shown as means 6 SEM. *P , 0.05.
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products formed at similar levels to TXA2 through the
action of group IV A cytosolic phospholipase A2 and
COX-1. Despite not having been previously reported as
platelet COX-1 products, this finding is consistent with an
earlier report that isolated COX-1 enzyme can directly
produce 11(R)-HETE, 15(R)-HETE, and 15(S)-HETEwhen
AA is present within the active site of the enzyme in dif-
ferent catalytically competent arrangements (20). We
hypothesize that this effect may be seen in strongly acti-
vated platelets where very high levels of AA can be re-
leased. Because our LC-MS/MS analyses could not
discriminate 15(R)-HETE from 15(S)-HETE, we used a
discriminatory immunoassay, which demonstrated 15(S)-
HETE as a major product.
In our studies we also noted that in blood, but not PRP,
the formation of 5-HETE increased robustly in response to
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Figure 2. LC-MS/MS analysis of the production of TXA2, PGE2, PGD2, 5-HETE, 11-HETE, 12-HETE, and 15-HETE by PRP and
whole blood in response to TRAP-6 in the presence of aspirin (100 mM), prasugrel (3 mM), or the combination of aspirin and
prasugrel. Whole blood and PRP from healthy volunteers pretreated with aspirin (100 mM), prasugrel (3 mM), or the
combination of aspirin and prasugrel was incubated for 30 min at 37°C in the presence of TRAP-6 (30 mM) or vehicle and then
centrifuged (1300 g; 24°C) to produce plasma samples. Stimulation of PRP (A–G) and whole blood (H–N) with TRAP-6
signiﬁcantly increased the levels of TXA2 (A, H), PGE2 (B, I), PGD2 (C, J ), 5-HETE (D, K), 11-HETE (E, L), 12-HETE (F,M), and
15-HETE (G, N), which were fully inhibited by aspirin or the combination of aspirin and prasugrel. The levels of 5-HETE and 12-
HETE were not affected by the presence of any treatment in either PRP or whole blood, except for the production of 12-HETE,
which was signiﬁcantly inhibited by aspirin and prasugrel in combination. Data are shown as means6 SEM (ANOVA with Dunnett
posttest; n = 4). *P , 0.05; ***P , 0.001.
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Figure 3. Effects of LTB4, 11-HETE, 15-HETE,
5-HETE, and the 12(S)-HETE stereoisomer on
neutrophil chemotaxis. The chemotactic re-
sponses of isolated neutrophils obtained from
human blood and stimulated with 11-HETE,
15-HETE, 5-HETE, 12(S)-HETE (0.3–3 mM), or
LTB4 (1–100 nM, as control) were studied using a
disposable Chemotaxis System. LTB4 (1, 10, or
100 nM) signiﬁcantly induced neutrophil chemo-
taxis, as did 5-HETE (3 mM) and 12(S)-HETE
(3 mM), whereas 11-HETE and 15-HETE were
without effects. Data are shown as means 6 SEM
(ANOVA with Dunnett posttest; n = 4). *P , 0.05;
***P , 0.01.
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Ca2+ ionophore (A23187) but not to the selective platelet
activators collagen or TRAP-6. This finding is consistent
with 5-HETE being a leukocyte product dependent upon
the activity of the 5-LOX enzyme and provides a useful
control for the selectivity and relevance of our assays.
Notably, and consistent with the discriminatory abilities
of our assays, the levels of 12-HETE in both blood and
PRP were not affected by the presence of aspirin or
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Figure 4. Effect of incubates of platelets acti-
vated by collagen or TRAP-6 in the presence or
absence of aspirin on HMEC-1 tube formation.
HMEC-1 cells were resuspended in platelet
incubates diluted with RPMI 1640 medium +
2% FBS and (1:1) and seeded (40,000 cells/
well) on a 48-well plate coated with growth
factor-reduced basement matrix extract. Plate-
let incubates contained human PRP stimulated
with collagen (30 mg/ml) or TRAP-6 (30 mM)
in the presence or absence of aspirin (100 mM)
which were added to the cell suspensions. A)
Tube formation was visualized using time-lapse
microscopy, where images were taken in phase
every 30 min for 16 h (Cell M software). Images
(original magniﬁcation, 310) were taken after
16 h incubation (37°C; 5% CO2) in phase or
after the addition of calcein AM. B) The number
of branching points was quantitated after 16 h
incubation using ImageJ software. Collagen-
stimulated or TRAP-6-stimulated platelets signiﬁ-
cantly increased HMEC-1 tube formation. This
effect was markedly reduced in response to
aspirin-treated platelets. Data are shown as
means 6 SEM (1-way ANOVA; n = 6). *P , 0.05.
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Figure 5. Effect of 15(S)-HETE on HMEC-1
tube formation in the presence of TRAP-6-
stimulated platelet releasates. HMEC-1 cells
were resuspended in platelet releasates diluted
with RPMI 1640 medium + 2% FBS and (1:1)
and seeded (40,000 cells/well) on a 48-well
plate coated with growth factor-reduced base-
ment matrix extract. Platelet releasates were
obtained by centrifugation of human PRP stim-
ulated with PBS or TRAP-6 (30 mM) in the
presence or absence of aspirin (100 mM). The
HMEC-1 cell suspensions were then treated
with platelet releasates plus vehicle or 15(S)-
HETE (1 mM). A) Tube formation was visual-
ized using time-lapse microscopy, where images
were taken in phase every 30 min for 16 h (Cell
M software). Images (original magniﬁcation,
310) were taken after 16 h incubation (37°C;
5% CO2) in phase or after the addition of
calcein AM. B–D) The number of branching
points was quantitated after 4 h (B), 8 h (C), and
16 h (D) incubation using ImageJ software.
TRAP-6-stimulated platelet releasates signiﬁcantly
increased HMEC-1 tube formation. This effect
was markedly reduced in response to releasates
prepared from aspirin-treated platelets, but fully
restored by addition of 15(S)-HETE (1 mM).
Data shown as means6 SEM (1-way ANOVA; n = 3).
*P , 0.05.
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prasugrel alone but were reduced when the drugs
were used in combination. This result is consistent with
dual antiplatelet therapy providing a general inhibition
of platelet activation with the consequent reduction of
AA release from the membrane phospholipids and thus
decreasing the levels of 12-HETE. The lack of effect of
aspirin against the production of 12-HETE provides fur-
ther evidence for the drug acting selectively on COX-1 in
our assays. Likewise, the lack of effect of PAM against the
production of 11-HETE and 15-HETE supports the con-
clusion that these are COX-1-dependent products (i.e., the
inhibition of their production caused by aspirin is not
explained by a reduction in platelet reactivity).
Having established that 11-HETE and 15(S)-HETE are
major COX-1 and aspirin-sensitive products of platelets,
we next sought to determine their functional roles. We
reasoned that the prime cellular targets of these hormones
werewithin the vasculature; thus,we focused onplatelets,
leukocytes, and vascular endothelial cells. We studied the
effects of exogenous 11(R)-HETE, 15(S)-HETE, and 15(R)-
HETE alongside the other COX-1 products we had iden-
tified on platelet aggregation in vitro using the proportions
found by our LC-MS/MS analysis and concentrations
previously reported as having relevant biologic activity
(12, 13).Particularly,we tested theTXA2-mimetic (U46619),
PGE2, and PGD2 together with 11(R)-HETE, 15(S)-HETE,
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Figure 6. Effect of 15(S)-HETE on formation of angiogenic sprouts from rat aortic rings in the presence of collagen or TRAP-6-
stimulated platelet releasates. Platelet releasates prepared as in Fig. 5 were diluted in Opti-MEM + 1% FBS (1:3) with the addition of
supplemental collagen or TRAP-6 and/or aspirin to provide common incubation solutions for all rings. Rings incubated with PBS
were treated without (A, H) or with (B, I) VEGF (10 ng/ml) or 15(S)-HETE (1 mM) (C, J), whereas rings incubated with releasates
from platelets treated with collagen (D–F) or TRAP-6 (K–M) were treated without or with 15(S)-HETE (1 mM). Once additions had
been made, aortic rings (5/condition) were incubated (37°C, 5% CO2) for 5 d. Images were taken in phase (original magniﬁcation,
34). G, N) The number of sprouts was determined using Cell Ml software. A, H) PBS alone did not stimulate formation of sprouts.
B, C, I, J) In contrast, the presence of VEGF signiﬁcantly increased the number of sprouts (B, I), whereas 15(S)-HETE produced a
moderate increase (C, J). D, E, K, L) Releasates from platelets stimulated with collagen (D) or TRAP-6 (K) signiﬁcantly promoted
the formation of sprouts, whereas releasates from platelets treated with aspirin had much weaker effects (E, L). F, M) The addition
of 15(S)-HETE (1 mM) to aspirin-treated platelet releasates restored the formation of angiogenic sprouts. One-sample test used to
compare differences to control response (PBS + VEGF; n = 3 for each). *P , 0.05.
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and 15(R)-HETE on platelets treated with aspirin to block
the effects of endogenous COX-1 products before stimu-
lationwith aspirin-sensitive concentrations of collagen.We
found that U46619 restored aggregation, which was then
partially inhibited by further addition of PGE2 and PGD2.
This confirmed the already well-known strong proag-
gregatory effects of TXA2, and the inhibitory effects of
PGD2 and high concentrations of PGE2, on platelet aggre-
gation. Addition of 11(R)-HETE, 15(R)-HETE, and 15(S)-
HETE in proportionsmatching those detected by LC-MS/
MS did not alter these aggregation responses.We noted in
these studies that the levels of TXB2 detected by LC-MS/
MS was of the order of 10-fold lower than the concentra-
tions of U46619 required to produce platelet activation
(0.1 vs. 2 mM). This is consistent with previous studies
andmay be explained by the differences in sampling from
the entire incubate volume comparedwith the amounts of
mediators present in the small spaces between interacting
platelets. Therefore, we focused upon the relative propor-
tions of the mediators to be added to the platelets. Overall,
these studies characterized the individual and net effects of
platelet COX-1 products on platelet activity and demon-
strated that these are not responses regulated by 11(R)-
HETE, 15(R)-HETE, or 15(S)-HETE when considered in a
proportionate manner to COX-1 products known to be
active, particularly TXA2, PGD2, and PGE2.
Having established a lack of effect of 11(R)-HETE,
15(R)-HETE, and 15(S)-HETE on acute platelet responses,
we next assessed their effects on inflammatory cells be-
cause HETEs are known to modulate neutrophil traffick-
ing and recruitment (21).We found that although 5-HETE
and 12(S)-HETE produced strong chemoattractant effects
on human neutrophils, as did the potent neutrophil-
derived chemoattractant LTB4, 11(R)-HETE, 15(R)-HETE,
and 15(S)-HETE were without effect.
Based on the evidence that 15(S)-HETE promotes an-
giogenic responses in both human dermal microvascular
endothelial cells and human umbilical vein endothelial
cells by up-regulating VEGF through the PIK3-Akt and
p38MAPKsignaling pathways,wenext assessedwhether
this enantiomer couldbe involved in angiogenic responses
using both in vitro and ex vivo models of angiogenesis
(22–25). Etulain et al. (26) have previously reported an
aspirin-sensitive angiogenic effect of platelet releasates
uponHMEC-1 cells. Using the same cell line, we similarly
found that incubates of activated platelets strongly pro-
moted the formation of angiogenic tubules and that this
was significantly reduced when platelets had been pre-
treated with aspirin. To explore these interactions further,
we centrifuged the activated platelet preparations before
addition to the HMEC-1 cells to focus particularly on the
platelet releasates producedduringplatelet activation and
not on other products or platelet components that could
interact with the cells over the much longer periods of cell
culture required to study indicators of angiogenesis. With
regard to the platelet incubates, releasates obtained from
agonist-stimulated platelets strongly promoted the for-
mation of angiogenic tubules byHMEC-1 cells in an aspirin-
sensitive manner, indicating that activated platelets
acutely produce a proangiogenic factor through the ac-
tivity of COX-1. We could then fully restore the response
by the addition of exogenous 15(S)-HETE at the concen-
trations tested above, suggesting that 15(S)-HETEwas the
COX-1-dependent proangiogenic product. A similar out-
come was seen in HMEC-1 migration. In direct accord
with these results using cultured cells, our ex vivo studies
clearly demonstrated that sprout formation from rat
aortic rings was promoted by releasates from stimu-
lated platelets but not by releasates prepared from
platelets treated with aspirin. Addition of exogenous
15(S)-HETE rescued this process from aspirin inhibition.
In summary, our results suggest that 15(S)-HETE,
formed as a direct COX-1 product, in combination with
other proangiogenic factors released by activated
platelets (e.g., VEGF and PDGF), is central to regulating
endothelial angiogenesis, particularly the formation of
tubule structures that represent the core of new vessels.
It has been established for many years that inhibition
of platelet COX-1 and consequent reduction in TXA2
production explains the ability of low-dose aspirin to
reduce thrombotic events. We suggest that the inhibi-
tion of 15(S)-HETE production by platelet COX-1 re-
ducing angiogenesis could provide a similarly clear
explanation for some of the cancer protective effects of
low-dose aspirin.
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